

Active substances set

Search phrase: sacituzumab govitecan

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Malignant breast cancer

Sacituzumab govitecan

Sacituzumab Govitecan as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.

 **NO REIMBURSEMENT**

 **ESMO**